ClinicalTrials.gg
CompletedNCT05007652Updated Feb 21, 2023

A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma

A Phase 2 interventional study of KRN125(pegfilgrastim), PLR001(plerixafor) and KRN8601(filgrastim), PLR001(plerixafor) in Multiple Myeloma and Malignant Lymphoma, sponsored by Kyowa Kirin Co., Ltd.. Completed at 21 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-02-21.

Sponsored by Kyowa Kirin Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 160 studies in Multiple Myeloma with a site in Japan — 34 open to participants now, 69 under way, 41 of them phase 3. Multiple Myeloma · Japan.

Enrollment
100th of 147
64 · median 186
Started
2021
with 12 others
Phase 2
26 of 160
4 open now
Registered
103rd of 160
by date

Among the 160 studies in Multiple Myeloma with a site in Japan, this one is the 100th largest by enrollment of the 147 interventional ones that give a count, is one of 13 that started in 2021, is one of 26 in phase 2, and was the 103rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

34 of the 160 studies in Multiple Myeloma with a site in Japan are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Multiple Myeloma with a site in Japan, or all of them as a file.
02

Study summary

To determine if KRN125 is non-inferior to filgrastim for the mobilization of hematopoietic stem cells into the peripheral blood in patients with multiple myeloma.

03

Conditions studied

  • Multiple Myeloma and Malignant Lymphoma
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Criteria for the multiple myeloma cohort

  • Patients with or pathologically diagnosed multiple myeloma
  • Patients who achieved CR, sCR, VGPR, and PR with induction therapy Criteria for the malignant lymphoma cohort
  • Patients with histologically or pathologically diagnosed malignant lymphoma
  • First or second CR or PR Multiple myeloma cohort, malignant lymphoma cohort common criteria
  • Patients aged 20 to 75 years or younger at the time of

Exclusion criteria

Exclusion Criteria:

  • Those who received hematopoietic stem cell transplantation (Allo-SCT), autologous hematopoietic stem cell transplantation (ASCT), or CAR-T therapy
  • Patients who have developed adverse events leading to discontinuation of hematopoietic stem-cell collection due to administration of granulocyte colony-stimulating factor (G-CSF) or apheresis
  • Patients who have not been able to collect adequate amounts of hematopoietic stem cells with G-CSF or plerixafor administration
  • Patients with to G-CSF or plerixafor
  • Patients with Performance status (PSs) of 2 or greater.
  • Patients whose cardiac or pulmonary conditions were judged to be inappropriate for apheresis or ASCT.
  • Pregnant or breastfeeding female patients
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    multiple myeloma cohort (KRN125)

    Drug: KRN125(pegfilgrastim), PLR001(plerixafor)

  • Active comparator
    multiple myeloma cohort (KRN8601)

    Drug: KRN8601(filgrastim), PLR001(plerixafor)

  • Experimental
    malignant lymphoma cohort

    Drug: KRN125(pegfilgrastim), PLR001(plerixafor)

Interventions

  • 7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.

  • 400 ug/m2 of KRN8601 from Day 1 to the end date of the Apheresis Once daily subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.

06

What researchers measure

Primary outcomes

  1. Achievement of a target of ≥ 2*10^6 CD34+ cells/kg collected during apheresis period in patients with multiple myeloma.

    Time frame: Day 5, 6, 7

Secondary outcomes

  1. Achievement of a target of ≥ 2*10^6 CD34+ cells/kg collected during apheresis period in patients with malignant lymphoma.

    Time frame: Day 1, 4, 5, 6, 7

Other outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs)

    Time frame: Day 30 or initiation of radiotherapy or chemotherapy

  2. Serum KRN125 concentrations

    Time frame: Day 30 or initiation of radiotherapy or chemotherapy

  3. Anti-KRN125 antibody

    Time frame: Day 30 or initiation of radiotherapy or chemotherapy

07

Study locations

21 sites
  • Nagoya City University Hospital
    Nagoya, Aichi, Japan
  • The Jikei University Kashiwa Hospital
    Kashiwa, Chiba, Japan
  • Hospital of the University of Occupational and Environmental Health
    Kitakyushu, Fukuoka, Japan
  • Hokkaido University Hospital of the National University Corporation
    Sapporo, Hokkaido, Japan
  • Kobe City Medical Center General Hospital
    Kobe, Hyogo, Japan
  • Ishikawa Prefectural Central Hospital
    Kanazawa, Ishikawa, Japan
  • Tokai University Hospital
    Isehara, Kanagawa, Japan
  • Kanagawa Cancer Center
    Yokohama, Kanagawa, Japan
  • Jichi Medical University Hospital
    Shimotsuke, Tochigi, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo, Japan
  • Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
    Bunkyo-ku, Tokyo, Japan
  • Japanese Red Cross Medical Center
    Shibuya-ku, Tokyo, Japan
  • Chiba Cancer Center
    Chiba, Japan
  • Kyushu University Hospital
    Fukuoka, Japan
  • Kagoshima University Hospital
    Kagoshima, Japan
  • Kochi Health Sciences Center
    Kochi, Japan
  • National Hospital Organization Kumamoto Medical Center
    Kumamoto, Japan
  • Niigata University Medical and Dental Hospital
    Niigata, Japan
  • National Hospital Organization Okayama Medical Center
    Okayama, Japan
  • Osaka International Cencer Institute
    Osaka, Japan
  • Wakayama Medical University Hospital
    Wakayama, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Oct 2022, 13 months.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 13 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2021
First posted
Aug 16, 2021
StartActual
Sep 1, 2021
Primary completionActual
Oct 25, 2022
CompletionActual
Oct 25, 2022
Last update
Feb 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05007652
Responsible party
Sponsor
First posted
Aug 16, 2021
Start date
Sep 1, 2021
Primary completion
Oct 25, 2022
Completion
Oct 25, 2022
Last update
Feb 21, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion